The FDA on May 14, 2025, approved WELIREG® for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic Pheochromocytoma or Paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL. WELIREG® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
